BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 26948350)

  • 21. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016.
    Malzkorn B; Reifenberger G
    Curr Opin Oncol; 2016 Nov; 28(6):494-501. PubMed ID: 27606698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular diagnostics of gliomas: the clinical perspective.
    Tabatabai G; Stupp R; van den Bent MJ; Hegi ME; Tonn JC; Wick W; Weller M
    Acta Neuropathol; 2010 Nov; 120(5):585-92. PubMed ID: 20862485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the molecular genetics of gliomas - implications for classification and therapy.
    Reifenberger G; Wirsching HG; Knobbe-Thomsen CB; Weller M
    Nat Rev Clin Oncol; 2017 Jul; 14(7):434-452. PubMed ID: 28031556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults.
    Rodriguez FJ; Vizcaino MA; Lin MT
    J Mol Diagn; 2016 Sep; 18(5):620-634. PubMed ID: 27444975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress in the application of molecular biomarkers in gliomas.
    Wang J; Su HK; Zhao HF; Chen ZP; To SS
    Biochem Biophys Res Commun; 2015 Sep; 465(1):1-4. PubMed ID: 26253473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive biomarkers in adult gliomas: the present and the future.
    Thomas L; Di Stefano AL; Ducray F
    Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
    Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
    Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.
    Lee J; Solomon DA; Tihan T
    J Neurooncol; 2017 Mar; 132(1):1-11. PubMed ID: 28064387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling.
    Soffietti R; Franchino F; Magistrello M; Pellerino A; Rudà R
    Prog Neurol Surg; 2018; 31():168-179. PubMed ID: 29393185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
    Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Personalized therapy for gliomas].
    Wick W; Hau P
    Nervenarzt; 2015 Jun; 86(6):692, 694-6, 698-700. PubMed ID: 26022855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glioma Subclassifications and Their Clinical Significance.
    Chen R; Smith-Cohn M; Cohen AL; Colman H
    Neurotherapeutics; 2017 Apr; 14(2):284-297. PubMed ID: 28281173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study.
    Hempel JM; Brendle C; Bender B; Bier G; Skardelly M; Gepfner-Tuma I; Eckert F; Ernemann U; Schittenhelm J
    J Neurooncol; 2018 Sep; 139(2):373-381. PubMed ID: 29667086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular genetics of gliomas.
    Appin CL; Brat DJ
    Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular neuro-oncology in clinical practice: a new horizon.
    Weller M; Pfister SM; Wick W; Hegi ME; Reifenberger G; Stupp R
    Lancet Oncol; 2013 Aug; 14(9):e370-9. PubMed ID: 23896276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches.
    Riemenschneider MJ; Reifenberger G
    Curr Opin Neurol; 2009 Dec; 22(6):619-24. PubMed ID: 19741528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Molecular Diagnostics in the Management of Patients with Gliomas.
    Wirsching HG; Weller M
    Curr Treat Options Oncol; 2016 Oct; 17(10):51. PubMed ID: 27501915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. O6 -methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: a review of current status.
    Suri V; Jha P; Sharma MC; Sarkar C
    Neurol India; 2011; 59(2):229-35. PubMed ID: 21483124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.